MedTrace Logo

The Effect of Aliskiren on Endothelial Function in Pre-Diabetes and Diabetes

NCT01165983 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 124

Last updated 2017-03-28

Study results available
· View outcomes & findings →

Summary

The purpose of this research is to study and determine the effects of Aliskiren on blood vessels and blood flow. The primary hypothesis is that Aliskiren will increase endothelial function by 30% or more in comparison to the placebo group.

Conditions

  • Diabetes Type 2

Interventions

DRUG

Placebo

0mg tablet, taken orally for 12 weeks daily

DRUG

Aliskiren

150mg tablet, taken orally for 12 weeks daily

Sponsors & Collaborators

Principal Investigators

  • Aristidis Veves, MD · Beth Israel Deaconess Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2012-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01165983 on ClinicalTrials.gov